Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Signs MOU to Mine High Grade Zone 2 at Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Relay Therapeutics Inc RLAY

Healthcare Biotechnology
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Ka), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.


NDAQ:RLAY - Post by User

Relay Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(181)
•••
Post by whytestockson Sep 09, 2024 10:15am
15 Views
Post# 36214621

Relay Therapeutics Announces Positive Interim Data for RLY-2

Relay Therapeutics Announces Positive Interim Data for RLY-2
NEWS: $RLAY Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival9.2-month median PFS in heavily pre-treated patients with PI3K&#x03B1;-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients &amp; 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discont...RLAY - Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested